

APC anti-mouse CD69 Antibody

Catalog# / Size	104513 / 25 µg 104514 / 100 µg
Clone	H1.2F3
Regulatory Status	RUO
Other Names	Very Early Activation Antigen (VEA), AIM, EA1, MLR3, gp34/28
Isotype	Armenian Hamster IgG
Description	CD69 is a 60 kD type II membrane protein composed of a 27/33 kD disulfide-linked homodimer, also known as Very Early Activation Antigen (VEA), AIM, EA1, MLR3, and gp34/28. It is expressed on a subset of thymocytes and platelets. CD69 is rapidly induced on activated T and B cells, neutrophils, and NK cells. It is a C-type lectin, closely related to the NKR-P1 and Ly-49 NK cell activation molecules. CD69 is involved in the early events of cell activation and thymocyte positive selection.

Product Details

Verified Reactivity	Mouse
Antibody Type	Monoclonal
Host Species	Armenian Hamster
Immunogen	Mouse dendritic epidermal T cell line Y245
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration	0.2 mg/ml
Storage & Handling	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested
Recommended Usage	Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Red Laser (633 nm)
Application Notes	The H1.2F3 antibody has been reported to augment T cell activation. Additional reported applications (for the relevant formats) include: <i>in vitro</i> T cell and NK cell activation ¹⁻³ , immunohistochemistry ^{4,5} , and immunoprecipitation ¹ . This antibody has been characterized in the literature as containing a lambda (?) light chain.

Application References

(PubMed link indicates BioLegend citation)

1. Yokoyama WM, *et al.* 1988. *J. Immunol.* 141:369. (IP)
2. Sobel ES, *et al.* 1993. *J. Immunol.* 150:673.
3. Karlhofer FM, *et al.* 1991. *J. Immunol.* 146:3662.
4. Zhou X, *et al.* 2005. *J. Biol. Chem.* 280:31240. (IHC)
5. Podd BS, *et al.* 2006. *J. Immunol.* 176:6532. (IHC)
6. Lawson BR, *et al.* 2007. *J. Immunol.* 178:5366.
7. Lee JW, *et al.* 2006. *Nature Immunol.* 8:181.
8. Epardaud M, *et al.* 2008. *Cancer Res.* 15:2972. [PubMed](#)
9. Jordan JM, *et al.* 2008. 76:3717. [PubMed](#)
10. Kenna TJ, *et al.* 2008. *Blood* 111:2091. [PubMed](#)
11. Ishikawa C, *et al.* 2013. *Biochim Biophys Acta.* 167:99. [PubMed](#)

Product Citations

1. Stepanek O, *et al.* 2013. J Immunol. 190:1807. [PubMed](#)
2. Kongsoomboonvech AK, *et al.* 2020. PLoS Pathog. 16:e1008327. [PubMed](#)
3. Su Y, *et al.* 2022. J Hematol Oncol. 15:99. [PubMed](#)
4. Michelet X, *et al.* 2015. J Immunol. 194:2079. [PubMed](#)
5. Català C, *et al.* 2022. iScience. 25:105078. [PubMed](#)
6. Files M, *et al.* 2022. NPJ Vaccines. 7:48. [PubMed](#)
7. Haque M, *et al.* 2021. STAR Protoc. 2:100264. [PubMed](#)
8. Diao L, *et al.* 2022. iScience. 25:105511. [PubMed](#)
9. del Rio ML, *et al.* 2021. Transl Res. Online ahead of print. [PubMed](#)
10. Bartleson JM, *et al.* 2020. Nat Immunol. 1384:21. [PubMed](#)
11. Qi X, *et al.* 2019. Nat Commun. 10:2141. [PubMed](#)
12. Wang Z, *et al.* 2021. J Immunother Cancer. 9: . [PubMed](#)
13. Yu AI, *et al.* 2020. Cell Rep. 107471:31. [PubMed](#)
14. Mitchell JE, *et al.* 2021. Cell Reports. 35(2):108966. [PubMed](#)
15. Zhuang Z, *et al.* 2021. J Exp Med. 218:00:00. [PubMed](#)
16. Lo W, Allen D 2012. Nat Immunol. 13:880. [PubMed](#)
17. Wang Z, *et al.* 2019. J Clin Invest. 130:4850. [PubMed](#)
18. Sasaki K, *et al.* 2019. Nat Commun. 10:3878. [PubMed](#)
19. Woyciechowski S, Hofmann M, Pircher H 2017. Eur J Immunol. 47:244-250. [PubMed](#)
20. Dolina JS, *et al.* 2020. Cell Rep. 107249:31. [PubMed](#)
21. Qu J, *et al.* 2018. J Immunol Res. 2018:7519856. [PubMed](#)
22. Marchingo JM, *et al.* 2020. eLife. 9:e53725. [PubMed](#)
23. Pauken KE, *et al.* 2020. Cell Reports. 31(13):107827. [PubMed](#)
24. MacDonald A, *et al.* 2021. Front Immunol. 12:755995. [PubMed](#)
25. Hojo MA, *et al.* 2019. Nat Commun. 2.224305556. [PubMed](#)
26. Lee J, *et al.* 2022. Clin Transl Med. 12:e1021. [PubMed](#)
27. Hrdinka M, *et al.* 2016. PLoS One. 11: 0162863. [PubMed](#)
28. Linehan JL *et al.* 2018. Cell. 172(4):784-796 . [PubMed](#)
29. Yue X, *et al.* 2019. Nat Commun. 10:2011. [PubMed](#)
30. Ramos RN, *et al.* 2022. Clin Transl Immunology. 11:e1392. [PubMed](#)
31. Xu L, *et al.* 2012. J Immunol. 188:248. [PubMed](#)
32. Noviski M, *et al.* 2018. Elife. 7:e35074. [PubMed](#)
33. LaFleur MW, *et al.* 2019. Nat Commun. 10:1668. [PubMed](#)
34. Shannon JP, *et al.* 2021. STAR Protoc. 2:100790. [PubMed](#)
35. Kim S, *et al.* 2021. Elife. 10: . [PubMed](#)
36. Shannon JP, *et al.* 2021. Immunity. 54(2):276-290.e5. [PubMed](#)
37. Morrison V, *et al.* 2015. J Immunol. 195: 105 - 115. [PubMed](#)
38. Henrich IC, *et al.* 2021. Cancer Res. 81:2171. [PubMed](#)
39. Evgin L, *et al.* 2020. Nat Commun. 2.671527778. [PubMed](#)
40. Wei Z, *et al.* 2021. Nat Commun. 0.805555556. [PubMed](#)
41. Xie X, *et al.* 2009. J Immunol. 182:7163. [PubMed](#)
42. Lebrun A, *et al.* 2015. J Immunol. 195: 4358 - 4368. [PubMed](#)
43. Nenasheva T, *et al.* 2017. PLoS One. 12(6):e0178983. [PubMed](#)
44. Li J, *et al.* 2020. Development. . [PubMed](#)
45. Shissler SC, *et al.* 2020. Sci Rep. 10:8218. [PubMed](#)
46. Okuma A, *et al.* 2021. Methods Mol Biol. 2312:3. [PubMed](#)
47. Elliot TAE, *et al.* 2021. Immunity. 54:2481. [PubMed](#)
48. Schaffert S, *et al.* 2015. J Immunol. 195: 1470-1479. [PubMed](#)
49. Yan C, *et al.* 2022. NPJ Precis Oncol. 6:6. [PubMed](#)
50. Wang R, *et al.* 2022. J Immunother Cancer. 10: . [PubMed](#)
51. Xu Y, *et al.* 2021. iScience. 24:103445. [PubMed](#)
52. Hsia HC, *et al.* 2017. J Leukoc Biol. 101:1053. [PubMed](#)
53. Sun Y, *et al.* 2022. iScience. 25:104846. [PubMed](#)
54. Olguin J, *et al.* 2015. Microbes Infect. 17: 586-595. [PubMed](#)
55. Lin Y, *et al.* 2012. Cancer Prev Res. 5:1090. [PubMed](#)
56. Mohammed RN, *et al.* 2019. Sci Rep. 4.185416667. [PubMed](#)

RRID

AB_492844 (BioLegend Cat. No. 104513)
AB_492843 (BioLegend Cat. No. 104514)

Antigen Details

Structure	C-type lectin, 27/33 kD
Distribution	Activated T cells and B cells, NK cells, granulocytes, thymocytes, platelets
Function	Lymphocyte activation
Cell Type	B cells, Granulocytes, NK cells, Platelets, T cells, Thymocytes, Tregs
Biology Area	Costimulatory Molecules, Immunology, Innate Immunity
Molecular Family	CD Molecules
Antigen References	1. Barclay AN, <i>et al.</i> 1997. The Leukocyte Antigen FactsBook Academic Press. 2. Testi R, <i>et al.</i> 1994. <i>Immunol. Today</i> 15:479.

3. Moretta A, *et al.* 1991. *J. Exp. Med.* 174:1393.
4. Yokoyama WM, *et al.* 1988. *J. Immunol.* 141:369.

Gene ID [12515](#)


Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

Other Formats

Biotin anti-mouse CD69, FITC anti-mouse CD69, PE anti-mouse CD69, PE/Cyanine5 anti-mouse CD69, Purified anti-mouse CD69, PE/Cyanine7 anti-mouse CD69, APC anti-mouse CD69, Alexa Fluor® 488 anti-mouse CD69, Alexa Fluor® 647 anti-mouse CD69, PerCP anti-mouse CD69, PerCP/Cyanine5.5 anti-mouse CD69, Pacific Blue™ anti-mouse CD69, Brilliant Violet 421™ anti-mouse CD69, APC/Cyanine7 anti-mouse CD69, Brilliant Violet 605™ anti-mouse CD69, Brilliant Violet 510™ anti-mouse CD69, Purified anti-mouse CD69 (Maxpar® Ready), PE/Dazzle™ 594 anti-mouse CD69, Brilliant Violet 711™ anti-mouse CD69, Alexa Fluor® 700 anti-mouse CD69, Brilliant Violet 650™ anti-mouse CD69, Brilliant Violet 785™ anti-mouse CD69, TotalSeq™-A0197 anti-mouse CD69, APC/Fire™ 750 anti-mouse CD69, TotalSeq™-C0197 anti-mouse CD69, TotalSeq™-B0197 anti-mouse CD69, KIRAVIA Blue 520™ anti-mouse CD69, Spark NIR™ 685 anti-mouse CD69, Spark Red™ 718 anti-mouse CD69

Product Data



Con A-stimulated C57BL/6 mouse splenocytes (2 days) stained with H1.2F3 APC

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587